Everyday Health Acquires Cambridge BioMarketing, the Leader in Strategic Launch and Marketing Solutions for Orphan and Rare Disease Products

Mar 23, 2015, 07:00 ET from Everyday Health, Inc.

NEW YORK and CAMBRIDGE, Mass., March 23, 2015 /PRNewswire/ -- Everyday Health, Inc. (NYSE: EVDY), a leading provider of digital health and wellness solutions, today acquired Cambridge BioMarketing Group, LLC, the leader in strategic launch and marketing solutions for orphan and rare disease products.

Everyday Health's acquisition of Cambridge BioMarketing will broaden its strategic marketing and communications solutions to pharmaceutical brands targeting the orphan and rare disease segments of the market. The orphan and rare disease market is estimated to grow from $90 billion in 2013 to $176 billion by 2020, accounting for approximately 19% of all branded-drug sales by 2020, up from approximately 9% percent in 2006. Commercializing in markets with small global patient populations requires sophisticated and highly targeted digital marketing capabilities. For existing Cambridge BioMarketing clients, the acquisition will add to the company's digital analytic, executional, and strategic services focused on these unique populations, while increasing access and visibility across a wide range of media channels.

"Cambridge BioMarketing has achieved great success providing innovative marketing solutions to launch and grow the leading brands in the fast-growing orphan and rare disease categories," said Ben Wolin, Co-Founder and CEO of Everyday Health. "We believe this acquisition makes us the premier digital partner for the leading pharmaceutical companies across their entire portfolio. We now service our pharmaceutical partners across the entire spectrum of their therapeutic areas, including orphan, specialty and mass market brands. In addition, we provide solutions throughout the entire lifecycle of pharmaceutical marketing -- from the strategic phase of pre-launch, during the growth years and maximizing a mature product. We believe we can truly be a one-stop shop for our customers." 

Everyday Health also intends to utilize its existing audience, content and data assets to enable Cambridge BioMarketing's customers to directly engage with consumers and healthcare professionals, as well as to provide more robust content offerings focused on orphan and rare diseases.  For example, Everyday Health's MedPage Today news platform will better educate physicians on the treatment of rare and orphan diseases and directly connect them with other healthcare professionals that treat these patients. Likewise, Everyday Health, through its existing relationship with MayoClinic.org, will leverage their premier content and tools focused on rare and orphan diseases.

Cambridge BioMarketing is based in Cambridge, Massachusetts and has approximately 70 employees with extensive clinical, creative, digital strategy and pharmaceutical marketing expertise that spans multiple stages of development and audiences ranging from patients to physicians to payors. Maureen Franco, Cambridge BioMarketing Chief Executive Officer, will continue to lead the Cambridge BioMarketing business together with the existing management team. 

"Accessing Everyday Health's large consumer and physician audiences will dramatically improve our ability to execute innovative marketing solutions across the growing orphan and rare disease therapeutic categories," said Ms. Franco. "Likewise, leveraging Everyday Health's leading sales force and relationships with collaborators such as Mayo Clinic will help us offer even more powerful solutions to existing clients, as well as diversify new offerings and insights."

Everyday Health paid $33 million to acquire Cambridge BioMarketing. In addition, the equity-holders of Cambridge BioMarketing are eligible to receive up to an additional $5 million in cash based on Cambridge BioMarketing's performance in calendar year 2015.

Petsky Prunier Securities LLC acted as exclusive financial advisor to Cambridge BioMarketing.

Teleconference Information
Everyday Health will discuss its acquisition of Cambridge BioMarketing and provide updated financial guidance during a teleconference today, March 23, 2015, at 8:30 AM ET. The conference call can be accessed at (877) 201-0168 or (647) 788-4901 (International), conference ID# 7412387 or via live webcast at http://ir.everydayhealth.com. The live webcast will include a supplemental investor presentation.

Following completion of the call, a recorded replay of the webcast and the investor presentation will be available on Everyday Health's website.  To listen to the telephone replay, call toll-free (855) 859-2056 or (404) 537-3406 (International), conference ID# 7412387. The telephone replay will be available from 11:30 AM ET March 23, 2015 through 11:59 PM ET March 30, 2015. Additional investor information can be accessed at http://ir.everydayhealth.com.

About Everyday Health, Inc.  
Everyday Health, Inc. (NYSE: EVDY) is a leading provider of digital health and wellness solutions. Everyday Health attracts a large and engaged audience of consumers and healthcare professionals to its premier health and wellness properties, and utilizes its data and analytics expertise to deliver highly personalized content experiences and efficient and effective marketing and engagement solutions. Everyday Health enables consumers to manage their daily health and wellness needs, healthcare professionals to stay informed and make better decisions for their patients, and marketers, health payors and providers to communicate and engage with consumers and healthcare professionals to drive better health outcomes. Everyday Health's content and solutions are delivered through multiple channels, including desktop, mobile web, and mobile phone and tablet applications, as well as video and social media.

About Cambridge BioMarketing Group, LLC
Founded in 2001, Cambridge BioMarketing is the leader in strategic launch and marketing solutions for orphan and rare disease products. Having launched some of the most successful orphan products ever, the Cambridge culture reflects its clients' extraordinary drive to deliver life-changing medicines to those who need them most: people and families facing devastating, underappreciated diseases.

Safe Harbor Provision
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements may be identified by their use of terms and phrases such as "anticipate," "enable," "expect," "will," "believe," "continue" and other similar terms and phrases, and such forward-looking statements include, but are not limited to, the statements regarding our future financial performance and statements regarding the expected impact of the acquisition of Cambridge BioMarketing. The outcome of the events described in these forward-looking statements is subject to known and unknown risks, uncertainties and other factors that could cause actual results to differ materially from the results anticipated by these forward-looking statements, including, but not limited to: our ability to attract and retain users to our portfolio of properties; our ability to attract and retain customers; the timing and amount of advertising spending by our current and future customers; our ability to effectively integrate the Cambridge BioMarketing acquisition; our ability to enter into new, or extend existing, partnership arrangements; our ability to successfully pursue opportunities in the broader health and wellness sectors; as well as those factors contained in the "Risk Factors" section of our Annual Report on Form 10-K for the year ended December 31, 2014 filed with the SEC on March 5, 2015 and our other SEC filings. All information in this release is as of today. Except as required by law, we undertake no obligation to update publicly any forward-looking statement made herein for any reason to conform the statement to actual results or changes in our expectations.

SOURCE Everyday Health, Inc.